As of 2025-12-06, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -2.20. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 1,405.83 mil USD. RXRX's TTM EBITDA according to its financial statements is -640.05 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 12.3x - 15.1x | 13.7x |
| Forward P/E multiples | 14.9x - 22.0x | 18.4x |
| Fair Price | (20.49) - (20.79) | (22.23) |
| Upside | -535.1% - -541.4% | -571.9% |
| Date | EV/EBITDA |
| 2025-12-05 | -2.20 |
| 2025-12-04 | -2.34 |
| 2025-12-03 | -2.16 |
| 2025-12-02 | -1.93 |
| 2025-12-01 | -1.96 |
| 2025-11-28 | -2.14 |
| 2025-11-26 | -1.99 |
| 2025-11-25 | -1.97 |
| 2025-11-24 | -1.94 |
| 2025-11-21 | -1.83 |
| 2025-11-20 | -1.61 |
| 2025-11-19 | -1.74 |
| 2025-11-18 | -1.82 |
| 2025-11-17 | -1.80 |
| 2025-11-14 | -1.81 |
| 2025-11-13 | -1.94 |
| 2025-11-12 | -2.16 |
| 2025-11-11 | -2.20 |
| 2025-11-10 | -2.06 |
| 2025-11-07 | -2.14 |
| 2025-11-06 | -2.14 |
| 2025-11-05 | -2.37 |
| 2025-11-04 | -2.39 |
| 2025-11-03 | -2.69 |
| 2025-10-31 | -2.75 |
| 2025-10-30 | -2.83 |
| 2025-10-29 | -2.98 |
| 2025-10-28 | -3.01 |
| 2025-10-27 | -3.27 |
| 2025-10-24 | -3.10 |
| 2025-10-23 | -2.89 |
| 2025-10-22 | -2.90 |
| 2025-10-21 | -3.15 |
| 2025-10-20 | -3.53 |
| 2025-10-17 | -2.98 |
| 2025-10-16 | -3.32 |
| 2025-10-15 | -3.61 |
| 2025-10-14 | -3.00 |
| 2025-10-13 | -2.75 |
| 2025-10-10 | -2.61 |
| 2025-10-09 | -3.01 |
| 2025-10-08 | -3.13 |
| 2025-10-07 | -2.55 |
| 2025-10-06 | -2.75 |
| 2025-10-03 | -2.73 |
| 2025-10-02 | -2.75 |
| 2025-10-01 | -2.46 |
| 2025-09-30 | -2.31 |
| 2025-09-29 | -2.33 |
| 2025-09-26 | -2.20 |